Osteoprotegerin independently predicts mortality in patients with stable coronary artery disease: The CLARICOR trial

Scandinavian Journal of Clinical and Laboratory Investigation

Volumn 74, Issue 8, 2014, Pages 657-664

  Bjerre, Mette ^a   Hilden, Jørgen ^b   Kastrup, Jens ^c   Skoog, Maria ^c   Hansen, Jørgen F ^d   Kolmos, Hans J ^e   Jensen, Gorm B ^f   Kjøller, Erik ^g   Winkel, P E R ^c   Flyvbjerg, Allan ^a   Gluud, Christian ^c   Lind, Inga ^h   Hildebrandt, Per ⁱ   Nielsen, Henrik ^j   Jespersen, Christian M ^d  

^a AARHUS UNIVERSITY   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c University of Copenhagen   (Denmark)

^d BISPEBJERG HOSPITAL   (Denmark)

^e ODENSE UNIVERSITY HOSPITAL   (Denmark)

^f HVIDOVRE HOSPITAL   (Denmark)

^g GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^h STATENS SERUM INSTITUT   (Denmark)

ⁱ FREDERIKSBERG HOSPITAL   (Denmark)

^j AMAGER HOSPITAL   (Denmark)

more..

Author keywords

Biomarker; Cardiovascular disease; Coronary artery disease; OPG; Osteoprotegerin

Indexed keywords

OSTEOPROTEGERIN; ANTIINFECTIVE AGENT; CLARITHROMYCIN; TNFRSF11B PROTEIN, HUMAN;

ADULT; AGE; AGED; ARTICLE; CARDIAC PATIENT; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; COHORT ANALYSIS; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DIABETIC PATIENT; FEMALE; FOLLOW UP; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; PROGNOSIS; PROTEIN BLOOD LEVEL; SURVIVAL; SURVIVOR; BLOOD; KAPLAN MEIER METHOD; MIDDLE AGED; MORTALITY; MULTICENTER STUDY (TOPIC); PROPORTIONAL HAZARDS MODEL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK FACTOR;

AGED; ANTI-BACTERIAL AGENTS; CLARITHROMYCIN; CORONARY ARTERY DISEASE; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MULTICENTER STUDIES AS TOPIC; OSTEOPROTEGERIN; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS;

EID: 84908610605     PISSN: 00365513     EISSN: 15027686     Source Type: Journal    
DOI: 10.3109/00365513.2014.930510     Document Type: Article

References (35)

1. Hofbauer LC, Shui C, Riggs BL, Dunstan CR, Spelsberg TC, O'Brien T, Khosla S. Effects of immunosuppressants on receptor activator of NF-kappaB ligand and osteoprotegerin production by human osteoblastic and coronary artery smooth muscle cells. Biochem Biophys Res Commun 2001;280:334-9.
2. Simonet WS, Lacey DL, Dunstan CR, Kelley M, Chang MS, Luthy R, Nguyen HQ, Wooden S, Bennett L, Boone T, Shimamoto G, DeRose M, Elliott R, Colombero A, Tan HL, Trail G, Sullivan J, Davy E, Bucay N, Renshaw-Gegg L, Hughes TM, Hill D, Pattison W, Campbell P, Sander S, Van G, Tarpley J, Derby P, Lee R, Boyle WJ. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 1997;89:309-19.
3. Reid P, Holen I. Pathophysiological roles of osteoprotegerin (OPG). Eur J Cell biol 2009;88:1-17.
4. Flyvbjerg A. Diabetic angiopathy, the complement system and the tumor necrosis factor superfamily. Nat Rev Endocrinol 2010;6:94-101.
5. Kiechl S, Werner P, Knoflach M, Furtner M, Willeit J, Schett G. The osteoprotegerin/RANK/RANKL system: a bone key to vascular disease. Expert Rev Cardiovasc Ther 2006;4:801-11.
6. Montecucco F, Steffens S, Mach F. The immune response is involved in atherosclerotic plaque calcification: could the RANKL/RANK/OPG system be a marker of plaque instability? Clin Dev Immunol 2007;2007:75805.
7. Vik A, Mathiesen EB, Noto AT, Sveinbjornsson B, Brox J, Hansen JB. Serum osteoprotegerin is inversely associated with carotid plaque echogenicity in humans. Atherosclerosis 2007;191:128-34.
8. Vik A, Mathiesen EB, Brox J, Wilsgaard T, Njolstad I, Jorgensen L, Hansen JB. Serum osteoprotegerin is a predictor for incident cardiovascular disease and mortality in a general population: the Tromso Study. J Thromb Haemost 2011;9:638-44.
9. Mogelvang R, Haahr-Pedersen S, Bjerre M, Frystyk J, Iversen A, Galatius S, Flyvbjerg A, Jensen JS. Osteoprotegerin improves risk detection by traditional cardiovascular risk factors and hsCRP. Heart 2013;99:106-10.
10. Pedersen S, Mogelvang R, Bjerre M, Frystyk J, Flyvbjerg A, Galatius S, Sorensen TB, Iversen A, Hvelplund A, Jensen JS. Osteoprotegerin predicts long-term outcome in patients with ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention. Cardiology 2012;123:31-8.
11. Omland T, Ueland T, Jansson AM, Persson A, Karlsson T, Smith C, Herlitz J, Aukrust P, Hartford M, Caidahl K. Circulating osteoprotegerin levels and long-term prognosis in patients with acute coronary syndromes. J Am Coll Cardiol 2008;51:627-33.
12. Fuernau G, Zaehringer S, Eitel I, de Waha S, Droppa M, Desch S, Schuler G, Adams V, Thiele H. Osteoprotegerin in ST-elevation myocardial infarction: prognostic impact and association with markers of myocardial damage by magnetic resonance imaging. Int J Cardiol 2013;167:2134-9.
13. Jono S, Otsuki S, Higashikuni Y, Shioi A, Mori K, Hara K, Hashimoto H, Ikari Y. Serum osteoprotegerin levels and long-term prognosis in subjects with stable coronary artery disease. J Thromb Haemost 2010;8:1170-5.
14. Pedersen E, Ueland T, Seifert R, Aukrust P, Schartum-Hansen H, Ebbing M, Bleie Ø, Igland J, Svingen G, Nordrehaug J, Nyga˚rd O. Serum osteoprotegerin levels and long-term prognosis in patients with stable angina pectoris. Atherosclerosis 2010;212:644-9.
15. Jespersen CM, Als-Nielsen B, Damgaard M, Hansen JF, Hansen S, Helo OH, Hildebrandt P, Hilden J, Jensen GB, Kastrup J, Kolmos HJ, Kjoller E, Lind I, Nielsen H, Petersen L, Gluud C. Randomised placebo controlled multicentre trial to assess short term clarithromycin for patients with stable coronary heart disease: CLARICOR trial. BMJ 2006;332:22-7.
16. Kjoller E, Hilden J, Winkel P, Frandsen NJ, G alatius S, Jensen G, Kastrup J, Hansen JF, Kolmos HJ, Jespersen CM, Hildebrandt P, Gluud C. Good interobserver agreement was attainable on outcome adjudication in patients with stable coronary heart disease. J Clin Epidemiol 2012;65:444-53.
17. Gluud C, Als-Nielsen B, Damgaard M, Fischer Hansen J, Hansen S, Helo OH, Hildebrandt P, Hilden J, Jensen GB, Kastrup J, Kolmos HJ, Kjoller E, Lind I, Nielsen H, Petersen L, Jespersen CM. Clarithromycin for 2 weeks for stable coronary heart disease: 6-year follow-up of the CLARICOR randomized trial and updated meta-analysis of antibiotics for coronary heart disease. Cardiology 2008;111:280-7.
18. Hansen S, Als-Nielsen B, Damgaard M, Helø OH, Petersen L, Jespersen CM. Intervention with clarithromycin in patients with stable coronary heart disease. Heart Drug 2001;1:14-9.
19. Jensen GB, Hilden J, Als-Nielsen B, Damgaard M, Hansen JF, Hansen S, Helo OH, Hildebrandt P, Kastrup J, Kolmos HJ, Kjoller E, Lind I, Nielsen H, Petersen L, Jespersen CM, Gluud C. Statin treatment prevents increased cardiovascular and all-cause mortality associated with clarithromycin in patients with stable coronary heart disease. J Cardiovasc Pharmacol 2010;55:123-8.
20. Winkel P, Hilden J, Fischer Hansen J, Hildebrandt P, Kastrup J, Kolmos HJ, Kjoller E, Jespersen CM, Gluud C, Jensen GB. Excess sudden cardiac deaths after short-term clarithromycin administration in the CLARICOR trial: why is this so, and why are statins protective? Cardiology 2011;118:63-7.
21. Mogelvang R, Pedersen SH, Flyvbjerg A, Bjerre M, Iversen AZ, Galatius S, Frystyk J, Jensen JS. Comparison of osteoprotegerin to traditional atherosclerotic risk factors and high-sensitivity C-reactive protein for diagnosis of atherosclerosis. Am J Cardiol 2012;109:515-20.
22. Harutyunyan MJ, Mathiasen AB, Winkel P, Gotze JP, Hansen JF, Hildebrandt P, Jensen GB, Hilden J, Jespersen CM, Kjoller E, Kolmos HJ, Gluud C, Kastrup J. High-sensitivity C-reactive protein and N-terminal pro-B-type natriuretic peptide in patients with stable coronary artery disease: a prognostic study within the CLARICOR trial. Scand J Clin Lab Invest 2011;71:52-62.
23. Lyngbaek S, Winkel P, Gotze JP, Kastrup J, Gluud C, Kolmos HJ, Kjoller E, Jensen GB, Hansen JF, Hildebrandt P, Hilden J, the CTG. Risk stratification in stable coronary artery disease is possible at cardiac troponin levels below conventional detection and is improved by use of N-terminal pro-B-type natriuretic peptide. Eur J Prev Cardiol. 2013 May 30. [Epub ahead of print]
24. Anand DV, Lahiri A, Lim E, Hopkins D, Corder R. The relationship between plasma osteoprotegerin levels and coronary artery calcification in uncomplicated type 2 diabetic subjects. J Am Coll Cardiol 2006;47:1850-7.
25. Jorsal A, Tarnow L, Flyvbjerg A, Parving HH, Rossing P, Rasmussen LM. Plasma osteoprotegerin levels predict cardiovascular and all-cause mortality and deterioration of kidney function in type 1 diabetic patients with nephropathy. Diabetologia 2008;51:2100-7.
26. Walus-Miarka M, Katra B, Fedak D, Czarnecka D, Miarka P, Wozniakiewicz E, Malecki M, Idzior-Walus B. Osteoprotegerin is associated with markers of atherosclerosis and body fat mass in type 2 diabetes patients. Int J Cardiol 2011;147:335-6.
27. Nybo M, Rasmussen LM. The capability of plasma osteoprotegerin as a predictor of cardiovascular disease: a systematic literature review. Eur J Endocrinol 2008;159:603-8.
28. Hosbond SE, Poulsen TS, Diederichsen AC, Nybo M, Rasmussen LM, Mickley H. Osteoprotegerin as a marker of atherosclerosis: a systematic update. Scand Cardiovasc J 2012;46:203-11.
29. Venuraju SM, Yerramasu A, Corder R, Lahiri A. Osteoprotegerin as a predictor of coronary artery disease and cardiovascular mortality and morbidity. J Am Coll Cardiol 2010;55:2049-61.
30. Van Campenhout A, Golledge J. Osteoprotegerin, vascular calcification and atherosclerosis. Atherosclerosis 2009;204:321-9.
31. Song TJ, Kim J, Yang SH, Park JH, Lee HS, Nam CM, Lee OH, Kim YD, Nam HS, Heo JH. Association of plasma osteoprotegerin levels with stroke severity and functional outcome in acute ischaemic stroke patients. Biomarkers 2012;8:738-44.
32. Browner WS, Lui LY, Cummings SR. A ssociations of serum osteoprotegerin levels with diabetes, stroke, bone density, fractures, and mortality in elderly women. J Clin Endocrinol Metab 2001;86:631-7.
33. Rasmussen LM, Tarnow L, Hansen TK, Parving HH, Flyvbjerg A. Plasma osteoprotegerin levels are associated with glycaemic status, systolic blood pressure, kidney function and cardiovascular morbidity in type 1 diabetic patients. Eur J Endocrinol 2006;154:75-81.
34. Kjoller E, Hilden J, Winkel P, Galatius S, Frandsen NJ, Jensen GB, Hansen JF, Kastrup J, Jespersen CM, Hildebrandt P, Kolmos HJ, Gluud C. Agreement between public register and adjudication committee outcomes in a cardiovascular randomized clinical trial. Am Heart J 2014 (accepted).
35. Hilden J, Gerds TA. A note on the evaluation of novel biomarkers: do not rely on integrated discrimination improvement and net reclassification index. Statistics Med 2013.